Physician profile
Howard Adler
NPI 1427006782
$5,851.43
in general payments reported to CMS, 2019-2025
50 companies · $27.01 in 2025
The $27.01 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,573 · 2020: $166 · 2021: $426 · 2022: $949 · 2023: $1,235 · 2024: $1,475 · 2025: $27.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,637 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,637.09 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $633.15 | 2019-2025 | Imbruvica, Rybrevant, Carvykti |
| Novartis Pharmaceuticals Corporation | $486.59 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $375.01 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $372.37 | 2019-2024 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $342.49 | 2019-2024 | |
| Genentech USA, INC. | $323.83 | 2019-2024 | Tecentriq, Polivy, Lunsumio |
| Genzyme Corporation | $320.74 | 2019-2024 | |
| Astellas Pharma US INC | $316.19 | 2019-2024 | Xospata, Padcev, Xtandi |
| Celgene Corporation | $253.34 | 2019-2024 | Reblozyl, Pomalyst, Opdualag |
| E.R. Squibb & Sons, L.L.C. | $216.66 | 2019-2024 | Opdivo, Opdualag |
| Abbvie INC. | $201.53 | 2019-2024 | Venclexta |
| Takeda Pharmaceuticals U.S.A., INC. | $174.80 | 2019-2024 | Alunbrig, Fruzaqla |
| Lilly USA, LLC | $164.38 | 2019-2024 | Jaypirca, Retevmo, Verzenio |
| Eisai INC. | $137.01 | 2019-2024 | |
| Mirati Therapeutics, INC. | $127.69 | 2023-2024 | Krazati |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Adler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.